Welcome to Multibagg AI
Log in to access personalized features
IRIS
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Research powered by GOALZEN CAPITAL SERVICES PRIVATE LIMITED · SEBI Research Analyst INH000013448
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Discovery themes featuring this stockBearish
3
Neutral
6
Bullish
5
Bearish
30
Neutral
9
Bullish
7
Bearish
27
Neutral
3
Bullish
2
Bearish
3
Neutral
6
Bullish
5
Bearish
3
Neutral
6
Bullish
5
Bearish
27
Neutral
3
Bullish
2
Bearish
27
Neutral
3
Bullish
2
Bearish
27
Neutral
3
Bullish
2
Ajooni Biotech Limited manufactures and supplies cattle feed, feed nutrients and animal healthcare supplements under its own brand AUTUS ANIMAL HEALTHCARE, serving institutional and increasingly B2C channels across northern India and expanding nationally through a dealer network.
The company reported strong top-line growth in FY2026 with revenue rising to Rs.18,237.81 lakhs from Rs.11,469.19 lakhs in FY2025, a roughly 59% year-on-year increase, while PAT increased to Rs.432.19 lakhs, reflecting operational scale-up and improved market traction for Ajooni Biotech.
Ajooni Biotech undertook material capital expenditure in FY2026, lifting gross fixed assets substantially and increasing inventories to Rs.3,945.51 lakhs; this build-up supports higher production but creates near-term working capital pressure visible in a sharp fall in cash balances for Ajooni Biotech.
The FY2026 statutory audit delivered an unmodified opinion and the auditors confirmed adequate internal financial controls; the company shows compliance with regulatory and reporting requirements, which supports credibility of the reported financials for Ajooni Biotech.
Management is executing a strategic shift to direct B2C distribution via a growing dealer network and geographic expansion, while relying on short-term borrowings and internal resources to fund capex and working capital needs for Ajooni Biotech.
Pharmaceuticals & Biotechnology
Pharmaceuticals
51 Cr
Low Risk
12.8
34.8
0.2
0.6
5.50
2.68
Sales CAGR
Profit CAGR
ROE
ROCE
Investor Presentation
Q4 FY26
Investor Presentation
Q1 FY26
Investor Presentation
Q3 FY25
Investor Presentation
Q2 FY25
Investor Presentation
Q4 FY24
Investor Presentation
Q4 FY24
Investor Presentation
Q4 FY22
Investor Presentation
Q3 FY21
Ajooni Biotech Ltd (AJOONI) is currently trading at 2.94 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Ajooni Biotech Limited manufactures and supplies cattle feed, feed nutrients and animal healthcare supplements under its own brand AUTUS ANIMAL HEALTHCARE, serving institutional and increasingly B2C channels across northern India and expanding nationally through a dealer network. The company reported strong top-line growth in FY2026 with revenue rising to Rs.18,237.81 lakhs from Rs.11,469.19 lakhs in FY2025, a roughly 59% year-on-year increase, while PAT increased to Rs.432.19 lakhs, reflecting operational scale-up and improved market traction for Ajooni Biotech. Ajooni Biotech undertook material capital expenditure in FY2026, lifting gross fixed assets substantially and increasing inventories to Rs.3,945.51 lakhs; this build-up supports higher production but creates near-term working capital pressure visible in a sharp fall in cash balances for Ajooni Biotech. The FY2026 statutory audit delivered an unmodified opinion and the auditors confirmed adequate internal financial controls; the company shows compliance with regulatory and reporting requirements, which supports credibility of the reported financials for Ajooni Biotech. Management is executing a strategic shift to direct B2C distribution via a growing dealer network and geographic expansion, while relying on short-term borrowings and internal resources to fund capex and working capital needs for Ajooni Biotech.
Over the past 52 weeks, Ajooni Biotech Ltd has traded between a low of ₹2.68 and a high of ₹5.50. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Ajooni Biotech Ltd has a market capitalization of approximately 50.64. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Ajooni Biotech Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 12.79 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 50.64 Cr, Ajooni Biotech Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Ajooni Biotech Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Ajooni Biotech Ltd is 12.79. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
| Symbol | Watchlist | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
6.11 | 51 Cr | -0.29 | 0.00 | 0.00 | 83.81 | -27.87 | -23.42 | ||
2.94 | 51 Cr | 12.79 | 0.56 | 0.00 | 4.74 | 5.92 | 3.29 | ||
28.17 | 46 Cr | 95.48 | 2.13 | 0.00 | 12.92 | 14.07 | 1.12 | ||
28.00 | 44 Cr | -1.16 | 0.46 | 0.00 | -43.08 | -15.40 | -12.14 | ||
33.00 | 43 Cr | -3.23 | 0.89 | 0.00 | -20.96 | -3.83 | -6.37 | ||
134.85 | 43 Cr | 7.25 | 1.05 | 1.48 | 14.16 | 19.37 | 12.34 | ||
9.27 | 40 Cr | -2.22 | 0.00 | 0.00 | -22.95 | -11.16 | -9.61 | ||
| Median: 7 Co. | — | 28.00 | 44 Cr | -0.29 | 0.56 | 0.00 | 4.74 | -3.83 | -6.37 |
